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Results: Cartilage pentosidine (a marker of AGE) levels were ~5 fold
enhanced (p =0.001 vs. PBS injected joints). The macroscopic and
microscopic damage was similar for the AGEd and PBS injected joints
(macroscopic score of 1 of a max score of 4 and histological OARSI score
of 3–5 of a max score of 36, respectively). For the PG synthesis (5.09±0.29
vs 4.64±0.32) % total and newly formed PG (23.29±1.88 vs 23.66±2.02
and 43.02±2.23 vs 43.75±2.4), as well as the PG content (31.20±1.17
vs 30.83±0.98) no statistically difference could be found between both
groups. This was not expected and therefore no control (untouched)
and OA (experimentally induced according to the classic Groove model)
joint were included in the study. Therefore, the biochemical data were
compared to historical controls of the most recent study using the Groove
model. Comparing these results, it demonstrates that the AGEd joints
are in general in between the PBS injected joints and the experimental
early OA joints (for example PG content 31.20±1.17 vs 30.83±0.98 vs
30.44±1.52). The PBS injected joints are in between the normal healthy
joints and the AGEd joints. Assuming a stepwise increase in severity of
damage there was a clear correlation between severity of damage and the
different conditions from healthy control joints, via PBS injected joints
with minimally surgically damage, AGEd joints with minimal surgical
damage, to experimentally induced OA joints according to the Groove
model (PG synthesis r = −0.873, % total and newly formed PG release
r = 0.971, p = 0.029 and r = 0.954, p = 0.046, and PG content r = 0.836).
Conclusions: Despite the fact that enhanced cross-linking of
macromolecules by the AGEs restrains loss of proteoglycans,
corroborating the diminished turnover of old cartilage, and a tendency
toward enhanced cartilage damage in the artiﬁcially aged joints, the
present data do not clearly support a role for enhanced cartilage AGE
levels in development of joint degeneration.
Biomarkers
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A UNIQUE DEAMIDATED CARTILAGE OLIGOMERIC MATRIX
PROTEIN (COMP) BIOMARKER PREFERENTIALLY IDENTIFIES HIP
OSTEOARTHRITIS
J. Catterall1, M-F. Hsueh1, T.V. Stabler1, J.M. Renner2, J.M. Jordan2,
V.B. Kraus1. 1Duke Univ., Durham, NC, USA; 2UNC, Chapel Hill, NC, USA
Purpose. As extracellular proteins age, they undergo and accumulate
non-enzymatic post-translational modiﬁcations that cannot be repaired.
As a tissue, such as cartilage, with a relatively slow protein turnover
ages, the levels of these modiﬁed proteins will increase. This allows the
exciting possibility of being able to distinguish “older” matrix proteins
released by catabolism, from turnover of newly synthesized proteins
or proteins released during times of frustrated repair. We hypothesized
that these modiﬁed proteins could be used to systemically monitor
loss of extracellular matrix due to chronic arthritic diseases such as
osteoarthritis (OA).
Method. To test this hypothesis, we predicted sites of deamidation in
human cartilage oligomeric matrix protein (COMP) and conﬁrmed, by
mass spectroscopy, the presence of deamidated (Asp64) and native
(Asn64) COMP epitopes [mean 0.95% deamidated COMP (D-COMP)
relative to native COMP] in cartilage. We developed monoclonal
antibodies speciﬁc to the deamidated Asp64 COMP region and a D-COMP
speciﬁc ELISA using the 6–1A12 monoclonal antibody, one of our newly
developed D-COMP speciﬁc antibodies. This new ELISA was used to
measure D-COMP in extracts from human cartilage and in human serum
to determine the utility of D-COMP as a novel biomarker for OA. For
comparison we determined the levels of serum Total COMP by ELISA
(antibodies 16-F12 and 17-C10). Cartilage extracts were prepared from
Duke IRB approved surgical waste cartilage, by grinding under liquid
nitrogen, two 4M Guanidine-HCL extractions before dialysis into PBS.
Results. In the Duke BAJA joint replacement study (n =14, mean age
63.4±13.2 yrs; 64% men; 4 hip and 10 knee replacements), serum
D-COMP (p =0.017), but not Total COMP (p =0.5), declined signiﬁcantly
after replacement suggesting an association of serum D-COMP levels with
OA joints. In 450 participants from the Johnston County Osteoarthritis
Project, D-COMP was associated with hip (p < 0.0001) but not knee
(p =0.95) OA severity as deﬁned by increasing Kellgren-Lawrence (KL)
grade. In contrast, Total COMP was associated with knee (p < 0.0001) but
not hip (p =0.47) KL grade. To further investigate D-COMPs association
with hip OA, we determined Total and D-COMP levels in hip (n =11; mean
age 77.3±11.3; 57–90 yrs) and knee cartilage extracts (n = 15; mean age
66.5±8.9; 54–88 yrs). D-COMP was higher in cartilage soluble proteins
extracted from hip proximal to OA lesions compared to macroscopically
normal hip (p = 0.007), or macroscopically normal and OA knee (p < 0.01)
cartilage. Total COMP did not vary by joint site or proximity to the
lesion.
Conclusions. Enrichment of deamidated epitope in hip cartilage likely
indicates a lesser repair response of hip compared with knee cartilage.
This study demonstrates the presence of D-COMP in articular cartilage
and the systemic circulation and to our knowledge, is the ﬁrst biomarker
to show speciﬁcity for a particular joint site.
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PROHIBITIN A NOVEL OSTEOARTHRITIS BIOMARKER: FROM THE
BENCH TO THE CLINIC
A. Moreau1,2, C. Picard1,2, J-F. Lavoie1,2, A. Franco1, M. Taheri1,
P. Lavigne3,2. 1Sainte-Justine Univ. Hosp. Res. Ctr., Montreal, QC, Canada;
2Universite´ de Montre´al, Montreal, QC, Canada; 3Maisonneuve-Rosemont
Hosp., Montreal, QC, Canada
Purpose: Several OA biomarkers are currently in development at
different validation stages. Unfortunately, there is no proven method
or test available to identify individuals at risk of developing primary OA,
or to identify which of the affected individuals may require treatment
due to the risk of disease progression. In this context, we have previously
identiﬁed Pitx1, a homeobox transcription factor, as a relevant OA
candidate gene. Indeed, a loss of PITX1 expression was determined
in patients suffering from primary knee joint OA. Recently, we have
identiﬁed Prohibitin (PHB1) as part of the transcriptional repressor
complex turning-off PITX1 expression in OA. Taking into account the
postulated role for PHB1 in cellular senescence and mitochondria
functions, it is conceivable that aberrant nuclear accumulation of PHB1
in primary OA could be detected not only in articular chondrocytes but
also in other cell types especially if this event is caused by genetic
predispositions.
Methods: To verify this assumption, cytosolic and nuclear fractions of
lymphocytes obtained from 88 consecutive OA patients and 33 aged-
matched control subjects were performed by Western blot while nuclear
localization of PHB1 in lymphocytes of OA patients (surgical cases)
was also detected using immunoﬂuorescence methods and confocal
microscopy. Plasma PHB1 levels were determined by an ELISA assay.
Results: Increased nuclear localization of PHB1 in lymphocytes of
OA patients (surgical cases) was detected by Western blot and
immunoﬂuorescence methods when compared to age-matched healthy
controls. Moreover, elevation in the number of nuclear aggregates
positive for PHB1 correlated with disease severity (KL score).
Interestingly, mean plasma PHB1 levels were signiﬁcantly decreased
in OA patients with an average value of 15.8 ng/ml and 21.4 ng/ml for
knee OA and hip OA groups when compared to the healthy control group
(30.1 ng/ml). This reduction in circulating PHB1 levels could be explained
by its nuclear retention.
Conclusions: Here we report a molecular mechanism that can help
to better stratify OA patients and the usefulness of PHB1 as OA
blood biomarker. Furthermore, our clinical data have the merit of
unifying previous concepts and ﬁndings proposed to better deﬁne OA
pathogenesis, such as mitochondrial dysfunction or cellular aging.
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EARLY DECREASE OF SERUM BIOMARKERS OF TYPE II COLLAGEN
DEGRADATION (Coll2–1) AND JOINT INFLAMMATION (Coll2–1NO2)
BY HYALURONIC ACID INTRA-ARTICULAR INJECTIONS IN PATIENTS
WITH KNEE OSTEOARTHRITIS
Y. Henrotin1, T. Conrozier2, M. Deberg3, A. Walliser-Lohse4, P. Richette5,
D. Mulleman6, B. Maillet7, F. Rannou8, C. Piroth9, P. Hilliquin10,
X. Chevalier11. 1Univ. of Liege, Liege, Belgium; 2Ctr. Hosp Lyon Sud, Pierre
Benite, France; 3Artialis SA, Liege, Belgium; 4Ctr. Hosp Belfort-Montbeliard,
Belfort, France; 5Lariboisiere Hosp, Paris, France; 6Trousseau Hosp, Tours,
France; 7Clinique St Odilon, Moulins, France; 8Cochin Hosp, Paris, France;
9Ctr. Hosp Dijon, Dijon, France; 10Ctr. Hosp Corbeil-Essonnes, Essonnes,
France; 11Henri Mondor Hosp, Cre´teil, France
Purpose: Viscosupplementation (VS) by intra articular (IA) injection
of hyaluronic acid (HA) is used to reduce pain in patients with knee
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osteoarthritis (K-OA). A previous study suggested a slowdown of type II
collagen degradation after VS as evidenced by a signiﬁcant of urine type
II collagen C telopeptide. To investigate in K-OA patients the effect of VS
on type II collagen degradation using serum Coll2–1, a peptide located
in triple helical part of type II collagen molecule, and its nitrated form
Coll2–1NO2.
Methods: Prospective open label study. 51 patients with unilateral
symptomatic K-OA (ACR criteria; Kellgren-Lawrence grade (KL) II to IV)
received an IA injection of 2ml of HA (hylan GF-20 a high molecular
weight cross-linked HA derivative) on days (D) 1, 7, 14 and were followed
3 months. At D-15 patients were examined and X-rays were performed,
in order to exclude patients with bilateral K-OA, or those with more than
3 OA joints including the target knee. From D-15 to D90 concomitant
therapies were unchanged. Walking pain (WP) on VAS was obtained
at each visit. Clinical response was deﬁned as a WP decrease >50%
between D1 and D90. S (S) samples were obtained, using a standardized
procedure, 2 weeks before the ﬁrst injection (D-15), then at D1 (1st
injection), D30 and D90. Coll2–1 and Coll2–1NO2 were measured directly
in the serum using speciﬁc immunoassays. Variations over time for
each biomarker were studied using Wilcoxon rank sum test. Predictive
factors of response were analyzed using univariate comparison and
logistic regression. Correlations between variables were obtained using
Spearman test.
Results: 45 patients (mean age 57.7, mean BMI 26.7) were analyzed.
Between D-15 and D1 there was no signiﬁcant difference for sColl2–1 and
sColl2–1NO2 biomarkers (all p > 0.05), indicating a good reproducibility
in serum measurements and the absence of spontaneous variation over
time. At D1, sColl2–1 and sColl2–1NO2 were unrelated to age, sex,
BMI, disease duration and WP. However, sColl2–1 and sColl2–1NO2
were signiﬁcantly higher in KL III/IV OA group than in KL I/II group
(p < 0.01). Variation of the biomarkers over time: Coll2–1 and Coll2–1NO2
decreased systematically and signiﬁcantly over time (Coll2–1/D1-D30:
p =0.0002; D1-D90: p =0.054; Coll2–1NO2/D1-D30: p =0.04; D1-D90:
p =0.025). The effect of HA was observed only in patients with the
most severe OA (KL III/IV). sColl2–1 at baseline was signiﬁcantly lower
in responders than in non responders (139.8(34.8) versus 167(45.1);
p = 0.03) even after adjustment for age, BMI and KL grade.
Conclusions: This study suggests a rapid slowdown of type II
collagen degradation and joint inﬂammation after viscosupplementation
with hylan GF-20. Coll2–1 and Coll2–1NO2 serum levels signiﬁcantly
decrease compared to baseline especially in patients with advanced
OA. Long term prospective trials are required to conﬁrm this potential
chondroprotective effect of HA.
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ASSOCIATION OF LUMBAR SPINE INDIVIDUAL RADIOGRAPHIC
FEATURES WITH URINARY CROSS-LINKED C-TELOPEPTIDE OF TYPE
II COLLAGEN (CTX-II) AND SERUM HYALURONAN: THE JOHNSTON
COUNTY OSTEOARTHRITIS PROJECT
A. Goode1, V. Kraus1, Y. Golightly2, S. Marshall2, J. Jordan2. 1Duke Univ.,
Durham, NC, USA; 2Univ. of North Carolina, Chapel Hill, NC, USA
Purpose: The association between osteoarthritis (OA) biomarkers and
lumbar spine individual radiographic features (IRF) has received little
investigation in the literature. Results have been conﬂicting regarding
the association between urinary cross-linked C-telopeptide of type II
collagen (uCTX-II) and disc space narrowing (DSN), and no association
has been found between uCTX-II and osteophytes (OST). No studies
have examined the association between lumbar spine IRF and serum
hyaluronan (sHA). Therefore, the two primary purposes of these analyses
were to: 1) determine if levels of uCTX-II and sHA reﬂect the presence
and severity of DSN and OST, controlling for the presence of knee OA
and 2) determine if these associations differ by gender or race.
Methods: Of the 1,015 participants enrolled in the Johnston County OA
Project from 2003–2004, lumbar spine IRF (DSN and OST) were available
for 547 participants with complete sHA data and 529 participants with
complete uCTX-II data (mean age 62.3 (SD 9.9), 61.8% female, 37.8%
African American, mean body mass index (BMI) 30.1 (SD 6.2), 29.2%
knee OA). Each lumbar spine level was graded in a semi-quantitative
fashion (0–3) according to the Burnett Atlas. From these grades, a
summary score from the ﬁve lumbar levels was developed separately
for each IRF (DSN and OST). The geometric mean and 95% conﬁdence
interval (CI) of uCTX-II and sHA levels were calculated across severity of
DSN and OST. Proportional odds and partial proportional odds models
were used to determine associations of DSN and OST severity with sHA
and uCTX-II. All analyses were adjusted for age, gender, race, BMI and
concomitant radiographic knee OA deﬁned as Kellgren-Lawrence score
of 2–4. Interactions were tested with likelihood ratio tests (p< 0.10) to
determine if associations differed signiﬁcantly by gender or race.
Results: Mean levels of uCTX-II increased with both severity of DSN
(p =0.002) and OST (p < 0.001). After adjustment, a one unit change
in uCTX-II was associated with 63% higher odds of more severe DSN
[adjusted odds ratio (aOR) = 1.63 (95% CI 1.27, 2.10)]. A strong association
was also seen for uCTX-II and the highest category of OST severity (aOR
= 3.24 (95% CI 1.89, 5.54).
In contrast, mean levels of sHA increased across severity of DSN
(p =0.010), whereas there was no association across severity of OST
(p =0.139). After adjustment, each one unit change in sHA, was associated
with increasing severity levels of DSN with ORs from 1.12 (95% CI 0.93,
1.35), 1.43 (95% CI 1.12, 1.83) and 2.25 (95% CI 1.51, 3.37). This effect was
predominantly seen in women (aOR = 1.34 (95% CI 1.09, 1.65), whereas
the association among men was close to the null (OR 0.95, (95% CI 0.68,
1.33). The association between sHA and OST severity was weak and of
borderline statistical signiﬁcance (aOR = 1.16 (95% CI 0.97, 1.38).
There effects were similar in both African Americans and Caucasians.
Conclusions: uCTX-II levels reﬂected increasing severity of lumbar DSN
and OST, above and beyond known associations between uCTX-II and
radiographic knee OA. This is the ﬁrst study to demonstrate that levels
of sHA differ according to severity of lumbar DSN, but are only weakly
associated with severity of lumbar OST. These ﬁndings underscore the
importance of analyzing IRFs for revealing biological insights through
biomarker studies.
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THE RELATIONSHIP BETWEEN MARKERS OF ARTICULAR CARTILAGE
METABOLISM AND POST-TRAUMATIC OSTEOARTHRITIS FOLLOWING
ACL RECONSTRUCTION
T.W. Tourville, M.E. Poynter, M.L. Roemhildt, J.R. Slauterbeck,
R.J. Johnson, B.D. Beynnon. Univ. of Vermont, Burlington, VT, USA
Purpose: Individuals who sustain a complete rupture of the anterior
cruciate ligament (ACL) are 40–80% more likely to also experience
subsequent degradation of tibiofemoral articular cartilage during the
years following injury regardless of surgical or non-surgical intervention.
The clinical corollary for this condition is early-onset post-traumatic
osteoarthritis (PTOA). Radiographic techniques serve as the current gold
standard for detecting the onset and monitoring the progression of
PTOA. Although these techniques are limited, they serve as a vital
research tool to monitor gross structural changes while attempting to
elucidate the pathophysiology of PTOA. The evaluation of biochemical
markers indicative of type-II collagen turnover in serum and urine is
thought to provide insight into the pathophysiology of the osteoarthritic
joint. Consequently, a substantial effort is underway to discover and
validate biomarkers that have the potential to overcome the limitations of
radiography, and help predict and/or monitor the onset and progression
of PTOA. The purpose of this investigation was to assess whether
levels of serum- and/or urine-based molecular markers of type-II
collagen metabolism are associated with joint space width change
(compared to the normal, contralateral limb, as well as to healthy control
subjects) 4 years following anterior cruciate ligament (ACL) injury and
reconstruction (ACL-R).
Methods: A prospective cohort with nested case-control study design
was used to evaluate markers of type-II collagen metabolism in 35
(18 women) ACL-R and 32 healthy matched control subjects (15 women)
of similar age, race, BMI, and activity level. Weight-bearing bilateral
AP view knee x-rays were obtained 1 and 4 year-post-ACL-R intervals;
and joint space width (JSW) determined using previously validated
techniques. Subjects were considered to have signiﬁcant JSW differences
(JSW-D) of their injured knee if the injured minus normal (contralateral)
knee difference fell outside ±2 standard deviations (SD) of the side-to-
side difference measured in controls. Serum and urine samples were
collected at each time point for the purpose of evaluating markers
of type-II collagen metabolism. Urinary degradation markers included
collagenase cleavage products of type II collagen (uC2C & uC1–2C
epitopes) and C-terminal cross-linked telopeptide of type-II collagen
(uCTX-II). Serum was obtained for the evaluation of the synthesis
marker C-propeptide of type II collagen (sCPII). These markers were
evaluated via commercially available enzyme-linked immunosorbent
